Estrella Immunopharma, Inc.
ESLA
Rank in Stocks
#26068
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise... Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Share Price
$0.5139
Last synced: 2026-11-09
Market Cap
$22.35M
Change (1 day)
36.93%
Change (1 year)
-75.53%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Estrella Immunopharma, Inc. (ESLA)
Category
Healthcare
EPS for Estrella Immunopharma, Inc. (ESLA)
EPS as of June 2026 TTM: $-0.25
According to Estrella Immunopharma, Inc.'s latest financial reports, its current EPS (TTM) is $-0.25. At the end of 2025 the company had an EPS of $-0.35, a decrease compared to its 2024 EPS of $-0.24.
EPS history for Estrella Immunopharma, Inc. from 2021 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.25 | -28.57% |
| 2025 | $-0.35 | 45.83% |
| 2024 | $-0.24 | -25.00% |
| 2022 | $-0.32 | 568.06% |
| 2021 | $-0.05 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -6,364.00% |
US
|
|
| $-7.07 | 2,728.00% |
US
|
|
| $-5.29 | 2,016.00% |
AU
|
|
| $12.88 | -5,252.04% |
BE
|
|
| $21.56 | -8,724.00% |
NL
|
Questions about Estrella Immunopharma, Inc.'s earnings per share (EPS)
What is Estrella Immunopharma, Inc.'s earnings per share (EPS)?
Estrella Immunopharma, Inc.'s earnings per share (EPS) over the last twelve months is $-0.25, as of Jun 2026.
What was Estrella Immunopharma, Inc.'s earnings per share (EPS) in 2025?
In 2025, Estrella Immunopharma, Inc.'s earnings per share (EPS) was $-0.35, compared with $-0.24 in 2024.
How has Estrella Immunopharma, Inc.'s earnings per share (EPS) changed since 2021?
From 2021 to 2025, Estrella Immunopharma, Inc.'s earnings per share (EPS) was highest in 2021 ($-0.05) and lowest in 2025 ($-0.35).
How does Estrella Immunopharma, Inc.'s earnings per share (EPS) compare with similar companies?
Estrella Immunopharma, Inc.'s earnings per share (EPS) ($-0.25) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.